Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$57.52 - $117.91
Previous CloseN/A
Volume488.69K
Average Volume (3M)3.12M
Market Cap
$32.15B
Enterprise Value$45.54B
Total Cash (Recent Filing)$2.70B
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)61.5
Beta1.11
Next Earnings
Jul 24, 2025EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding392,107,500
10 Day Avg. Volume2,489,919
30 Day Avg. Volume3,117,272
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)20.68
Price to Sales (P/S)0.00
P/FCF Ratio144.72
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue2.83
Enterprise Value/Gross Profit18.49
Enterprise Value/Ebitda11.85
Forecast
1Y Price Target
$99.39Price Target Upside19.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Dexcom News
Bulls Say, Bears Say
Bulls Say
Financial ConfidenceDXCM announced a new $750MM share buyback, indicating confidence in its financial position.
Market ExpansionThe expansion to cover Type 2 non-insulin patients represents a significant growth opportunity for DXCM.
Product InnovationDXCM received FDA approval for a 15-day product, reducing risk.
Bears Say
Cost PressuresDXCM lowered its FY25 GM guidance to 62% due to higher inventory replenishment costs.
Margin ChallengesMargins came in below consensus due to supply chain issues and increased shipping costs.
Ownership Overview
0.48% Insiders
29.02% Mutual Funds
25.14% Other Institutional Investors
17.07% Public Companies and Individual Investors
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $57.52 and its highest was $117.91 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $32.15B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 24, 2025 which is in 37 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on May 01, 2025. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.327 by -$0.007.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.45.
How many shares outstanding does Dexcom have?
Dexcom has 392,107,500 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.32 in its last earnings report, missing expectations of $0.327. Following the earnings report the stock price went up 16.169%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.39 (19.75% Upside)
$99.39 (19.75% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $432.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.95%
12-Months-Change
Fundamentals
Return on Equity
23.72%
Trailing 12-Months
Asset Growth
4.16%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, significant expansion in coverage for type 2 diabetes, and successful product innovations. However, challenges included a decline in gross margin due to supply chain issues and an FDA warning letter that required attention. Overall, while there are notable achievements, the presence of significant challenges suggests a balanced sentiment.Read More>DXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$99.39
▲(19.75%Upside)